ArticleScientific reports2017
Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Chitosan nanoparticles for mucosal and needle-free vaccination.NPJ vaccines · 2026Review
- Immunomodulatory Nanomaterials: Design Strategies, Mechanisms, Biomedical Applications, and Future Perspectives.Biomedicines · 2026Review
- The frequency and function of nucleoprotein-specific CD8Journal of virology · 2024Article
- A review of immune modulators and immunotherapy in infectious diseases.Molecular and cellular biochemistry · 2024Review
- Charge neutralized poly(β-amino ester) polyplex nanoparticles for delivery of self-amplifying RNA.Nanoscale advances · 2024Article
- Review
- Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.Journal of microbiology and biotechnology · 2021Article
- Polymeric nanoparticle vaccines to combat emerging and pandemic threats.Biomaterials · 2021Review
- Article
- Improving immunological insights into the ferret model of human viral infectious disease.Influenza and other respiratory viruses · 2019Review
- Food Additives as Novel Influenza Vaccine Adjuvants.Vaccines · 2019Article
- Immunomodulatory Nanosystems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.Frontiers in immunology · 2019Article
- Stimulatory effects of amino acids on γ-polyglutamic acid production by Bacillus subtilis.Scientific reports · 2018Article
- A Perspective on Nanoparticle Universal Influenza Vaccines.ACS infectious diseases · 2018Review
- Influences of nanocarrier morphology on therapeutic immunomodulation.Nanomedicine (London, England) · 2018Article
- Nano-selenium and its nanomedicine applications: a critical review.International journal of nanomedicine · 2018Review
- Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus.International journal of nanomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2009, the global outbreak of an influenza pandemic emphasized the need for an effective vaccine adjuvant. In this study, we examined the efficacy of poly-γ-glutamic acid/chitosan (PC) nanogel as an adjuvant for the influenza vaccine. PC nanogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity. Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologous and heterosubtypic [A/Philippines/2/82 (H3N2)] virus challenges. However, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.